Intravitreal Injections of Ziv-aflibercept for Macular Diseases
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Diabetic macular edema (DME), wet-AMD and macular edema secondary to vein occlusions are the
leading cause of blindness in developed countries. Several therapies have been studied as
such laser treatment and intravitreal injections of corticosteroids or anti-VEGF drugs. In
terms of public health the long term treatment with the current available drugs is very
expensive and new therapies with the same or better effect should be investigated. This study
intends to evaluate the efficacy and safety of intravitreal injections of ziv-aflibercept for
the treatment of patients with DME, wet-AMD and macular edema secondary to vein occlusions.